Goldman Sachs downgrades Glaxo to “sell” – Forbes

Goldman Sachs downgrades Glaxo to "sell"
Forbes
AP , 05.31.11, 10:57 AM EDT WASHINGTON — A Goldman Sacks analyst says GlaxoSmithKline's stock is overvalued as the British drugmaker prepares to face lower sales of its best-selling product, the asthma inhaler Advair. Goldman analyst Mark Beards notes
Goldman Downgrades GSK as Growth Won't Support ValuationBarron’s (blog)
Goldman Sachs downgrades Glaxo to "sell"CBS MoneyWatch.com

all 10 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *